Page 1321 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

6 References

purpura and the hemolytic-uremic syndrome. N Engl J Med. 177. Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated
1998;339(22):1578-1584. hemolytic uremic syndrome revisited in the era of complement
160. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum gene mutations. J Am Soc Nephrol. 2010;21(5):859-867.
lactate dehydrogenase elevation in patients with thrombotic 178. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13
thrombocytopenic purpura. J Clin Apheresis. 1998;13(1):16-19. autoantibodies in patients with thrombotic microangiopa-
161. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada thies and other immunomediated diseases. Blood. 2005;106(4):
A, Rossi E. Changes in health and disease of the metallopro- 1262-1267.
tease that cleaves von Willebrand factor. Blood. 2001;98(9): 179. Thampi S, Salmi D, Imashuku S, Ducore J, Satake N. Thrombotic
2730-2735. thrombocytopenic purpura in a child with systemic lupus ery-
162. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von thematosus. J Pediatr Hematol Oncol. 2011;33(3):221-223.
Willebrand factor regulate ADAMTS13, its major cleaving pro- 180. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S,
tease. Br J Haematol. 2004;126(2):213-218. Fujimura Y. Heterogeneous pathogenic processes of thrombotic
163. Loirat C, Saland J, Bitzan M. Management of hemolytic uremic microangiopathies in patients with connective tissue diseases.
syndrome. Presse Med. 2012;41(3, pt 2):e115-e135. Thromb Haemost. 2009;102(2):371-378.
164. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in 181. Weissenborn K, Donnerstag F, Kielstein JT, et al. Neurologic
thrombotic thrombocytopenic purpura-hemolytic uremic syn- manifestations of E coli infection-induced hemolytic-uremic
drome: relation to presenting features and clinical outcomes in syndrome in adults. Neurology. 2012;79(14):1466-1473.
a prospective cohort of 142 patients. Blood. 2003;102(1):60-68. 182. Zheng XL, Pallera AM, Goodnough LT, Sadler JE, Blinder MA.
165. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific Remission of chronic thrombotic thrombocytopenic purpura
von Willebrand factor-cleaving protease in thrombotic after treatment with cyclophosphamide and rituximab. Ann
microangiopathies: a study of 111 cases. Blood. 2001;98(6): Intern Med. 2003;138(2):105-108.
1765-1772. 183. Moake JL, Byrnes JJ, Troll JH, et al. Effects of fresh-frozen
166. Miner ME, Kaufman HH, Graham SH, Haar FH, Gildenberg plasma and its cryosupernatant fraction on von Willebrand fac-
PL. Disseminated intravascular coagulation fibrinolytic syn- tor multimeric forms in chronic relapsing thrombotic thrombo-
drome following head injury in children: frequency and prog- cytopenic purpura. Blood. 1985;65(5):1232-1236.
nostic implications. J Pediatr. 1982;100(5):687-691. 184. Molinari E, Costamagna L, Perotti C, Isernia P, Pagani A,
167. Kaneko T, Wada H. Diagnostic criteria and laboratory tests for Salvaneschi L. Refractory thrombotic thrombocytopenic pur-
disseminated intravascular coagulation. J Clin Exp Hematop. pura: successful treatment by plasmapheresis with plasma cryo-
2011;51(2):67-76. supernatant. Haematologica. 1993;78(6):389-392.
168. Levi M, van der Poll T. Disseminated intravascular coagulation: 185. Obrador GT, Zeigler ZR, Shadduck RK, Rosenfeld CS, Hanrahan
a review for the internist. Intern Emerg Med. 2012;8(1):23-32. JB. Effectiveness of cryosupernatant therapy in refractory and
169. Bates SM. D-dimer assays in diagnosis and management of chronic relapsing thrombotic thrombocytopenic purpura. Am J
thrombotic and bleeding disorders. Semin Thromb Hemost. Hematol. 1993;42(2):217-220.
2012;38(7):673-682. 186. Perotti C, Torretta L, Molinari E, Salvaneschi L. Cryoprecipitate-
170. Martin K, Borgel D, Lerolle N, et al. Decreased ADAMTS13 (A poor plasma fraction (cryosupernatant) in the treatment of
disintegrin-like and metalloprotease with thrombospondin type thrombotic thrombocytopenic purpura at onset. A report of
1 repeats) is associated with a poor prognosis in sepsis-induced four cases. Haematologica. 1996;81(2):175-177.
organ failure. Crit Care Med. 2007;35(10):2375-2382. 187. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC.
171. Nguyen TC, Han YY, Kiss JE, et al. Intensive plasma exchange Cryosupernatant as replacement fluid for plasma exchange
increases a disintegrin and metalloprotease with thrombospon- in thrombotic thrombocytopenic purpura. Members of
din motifs-13 activity and reverses organ dysfunction in chil- the Canadian Apheresis Group. Br J Haematol. 1996;94(2):
dren with thrombocytopenia-associated multiple organ failure. 383-386.
Crit Care Med. 2008;36(10):2878-2887. 188. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of
172. Yilmaz AA, Can OS, Oral M, et al. Therapeutic plasma exchange severe thrombotic thrombocytopenic purpura with the mono-
in an intensive care unit (ICU): a 10-year, single-center experi- clonal antibody rituximab. Am J Hematol. 2002;71(2):105-108.
ence. Transfus Apher Sci. 2011;45(2):161-166. 189. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for
173. Weiner C. Thrombotic microangiopathy in pregnancy and the refractory thrombotic thrombocytopenic purpura. Blood Cells
postpartum period. Semin Hematol. 1987;24:119-129. Mol Dis. 2002;28(3):385-391.
174. Stella CL, Dacus J, Guzman E, et al. The diagnostic dilemma 190. Tsai HM, Shulman K. Rituximab induces remission of cerebral
of thrombotic thrombocytopenic purpura/hemolytic uremic ischemia caused by thrombotic thrombocytopenic purpura. Eur
syndrome in the obstetric triage and emergency department: J Haematol. 2003;70(3):183-185.
lessons from 4 tertiary hospitals. Am J Obstet Gynecol. 2009; 191. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM.
200(4):381-386. Rituximab for chronic recurring thrombotic thrombocyto-
175. Martin JN Jr, Bailey AP, Rehberg JF, Owens MT, Keiser SD, May penic purpura: a case report and review of the literature. Br J
WL. Thrombotic thrombocytopenic purpura in 166 pregnan- Haematol. 2004;124(6):787-795.
cies: 1955-2006. Am J Obstet Gynecol. 2008;199(2):98-104. 192. Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive
176. Brown JH, Tellez J, Wilson V, et al. Postpartum aHUS second- treatment in patients with thrombotic thrombocytopenic pur-
ary to a genetic abnormality in factor H acquired through liver pura and evidence of anti-ADAMTS13 autoantibodies. Thromb
transplantation. Am J Transplant. 2012;12(6):1632-1636. Haemost. 2009;101(2):233-238.

Section07-O-ref.indd 6 1/21/2015 11:26:49 AM